Just reported
From Illumina's results release of 29 października 2026; its quarterly report has since been filed.
Actual
1,13B USD
+4,2% y/y
-2,6% q/q
Guided
—
No guide given
Actual
1,43 USD
+46% y/y
+5,9% q/q
Guided
—
No guide given
Actual
305M USD
+34% y/y
+24% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Udziały w przychodach to szacunki za quarter ended 2026-03-31, a nie dane z raportu złożonego do regulatora.
NovaSeq X
A high-throughput DNA-sequencing machine used by customers that need to process large numbers of samples.
MiSeq i100
A lower-throughput DNA-sequencing machine for labs running smaller or more project-based batches.
NovaSeq 6000
A high-throughput DNA-sequencing machine that some customers continue to use alongside newer systems.
StrataMap Spatial
A sequencing-based workflow that helps researchers study biological activity in specific locations within tissue.
SomaScan and SomaSeq
Tools for measuring proteins and connecting protein measurements with genetic information.
Billion Cell Atlas
A large collection of data on how cells respond to genetic changes, sold to drug companies for biological research and drug discovery.
Pełne sprawozdania finansowe →
Illumina makes machines that read DNA and sells the chemicals and other supplies customers use to run samples on them. Hospitals and clinical laboratories use sequencing for applications such as cancer testing, inherited-disease testing and screening; researchers and drug companies use it to study biology and develop medicines. Illumina also sells tools for measuring proteins and provides biological data and related services.
Zbudowane z własnych raportów spółki Illumina, Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
209,61 USD-1,5%zamknięcie 12 lis
Dane do 27 września 2026, z raportu 10-Q złożonego 30 października 2026
Illumina sells DNA-sequencing kits and machines to medical laboratories, hospitals, universities and drug companies.
The themes Illumina is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A+
Pasek pod ceną pokazuje ocenę w każdym dniu, wyliczoną wyłącznie z dokumentów, które były wtedy już publiczne.
Pokazujemy 2 z 41 kwartałów historii ocen spółki Illumina, Inc.. Pozostałe 39 sięgają do listopad 2016.
